Ozempic vs Mounjaro: The Self-Pay Trap Both Share
Here is the thing most comparisons skip: neither Ozempic nor Mounjaro has a manufacturer self-pay program. NovoCare's discount pricing runs through Wegovy; LillyDirect's runs through Zepbound. Both Ozempic and Mounjaro are structurally the more expensive cash-pay option for their own molecule. Below: what that actually means for your wallet, the honest efficacy comparison for diabetes patients, and when you should be looking at the weight-loss siblings instead.
Weight loss comparison (220 lbs starting weight)
% of body weight lost over 18 months, modeled from phase 3 trial data
Monthly cost by payment channel
| Channel | Ozempic | Mounjaro |
|---|---|---|
| Insurance copay (T2D, typical) | $63 | $88 |
| Manufacturer self-pay | - | - |
| Branded telehealth | $399 | $499 |
| Compounded (limited availability) | $199 | $299 |
| Cash retail (full WAC) | $998 | $1,069 |
"Manufacturer self-pay: None" is not a data gap - it is the actual policy. Compare this to Wegovy ($$349/mo NovoCare) and Zepbound ($$299/mo LillyDirect) - the weight-loss siblings of these exact molecules.
Why cash-pay patients get funneled to Wegovy and Zepbound
Novo Nordisk and Eli Lilly built their self-pay discount infrastructure specifically around the weight-loss-indicated brands, not the diabetes brands - even though the molecule inside the vial or pen is identical. This is almost certainly a deliberate segmentation strategy: diabetes patients have a much higher rate of insurance coverage (T2D diagnosis codes trigger formulary coverage far more reliably than weight-loss codes), so the manufacturers don't need a self-pay discount program on that side of the business the way they do to capture the much larger uninsured/denied weight-loss market.
The practical upshot: if you are cash-pay and do not have type 2 diabetes, the diabetes brand is almost never the right choice on cost grounds. If you DO have type 2 diabetes, check whether your insurance covers the diabetes brand before assuming you need to go cash-pay at all - coverage rates for Ozempic and Mounjaro under a T2D diagnosis are meaningfully higher than for Wegovy or Zepbound under a weight-loss diagnosis.
Where to actually buy Ozempic or Mounjaro (and the cheaper alternatives)
Manufacturer direct prices (LillyDirect, NovoCare) are usually cheapest. Updated May 2026.
| Drug | Insurance | Mfr direct | Telehealth (brand) | Telehealth (compd) | Cash retail | Get it |
|---|---|---|---|---|---|---|
| Wegovy 14.9% weight loss | $63 | $349 | $329 | $249 cheapest | $1,349 | Get →ad |
| Ozempic 11.6% weight loss | $63 | - | $399 | $199 cheapest | $998 | Get →ad |
| Wegovy (oral 25mg) 13.6% weight loss | $63 | $149 cheapest | $449 | - | $1,349 | Get →ad |
| Zepbound 22.5% weight loss | $88 | $299 cheapest | $499 | $299 cheapest | $1,059 | Get →ad |
| Mounjaro 20.9% weight loss | $88 | - | $499 | $299 cheapest | $1,069 | Get →ad |
| Saxenda 8.4% weight loss | $63 | - | $399 cheapest | - | $1,349 | Get →ad |
| Foundayo (orforglipron) 14.7% weight loss | $63 | $149 cheapest | - | - | $1,099 | Get →ad |
Frequently asked questions
Why does neither Ozempic nor Mounjaro have a manufacturer self-pay program?
Both manufacturers deliberately structure their self-pay programs around the weight-loss-indicated sibling brand instead. Novo Nordisk's NovoCare self-pay pricing runs through Wegovy, not Ozempic. Eli Lilly's LillyDirect self-pay vials are Zepbound-only, not Mounjaro. Same molecules (semaglutide in both Ozempic/Wegovy; tirzepatide in both Mounjaro/Zepbound), different self-pay economics depending on which FDA indication the brand carries. This is a business decision by both manufacturers, not a regulatory requirement - and it means cash-pay patients on the diabetes-indicated brand are structurally worse off than they would be on the weight-loss brand, even for the identical drug.
If I do not have diabetes, should I even be looking at Ozempic or Mounjaro?
Probably not, if cost is a factor. If you do not have type 2 diabetes, you have no path to insurance coverage for either drug (both are FDA-approved for T2D, and off-label weight-loss prescriptions are routinely denied), and you have no manufacturer self-pay program either. Cash-pay patients without diabetes are almost always better served by the weight-loss-indicated siblings: Wegovy has NovoCare self-pay at $349/mo, Zepbound has LillyDirect vials from $299/mo. This guide exists because a lot of search traffic asks "Ozempic vs Mounjaro" without realizing the honest answer, for most non-diabetic cash-pay searchers, is "neither - look at Wegovy or Zepbound instead."
For patients who DO have type 2 diabetes, which is better - Ozempic or Mounjaro?
Mounjaro (tirzepatide) generally shows stronger glycemic control and weight-loss data than Ozempic (semaglutide) in head-to-head and cross-trial comparisons - the dual GLP-1/GIP mechanism produces both better A1C reduction and more weight loss in most published comparisons. Off-label weight-loss context: Mounjaro's SURPASS trials showed around 20.9% weight loss versus Ozempic's roughly 11.6% in comparable populations. But "better" for a diabetes patient also depends on which drug your insurance actually covers on your specific formulary - a covered Ozempic often beats an uncovered Mounjaro on real-world cost, regardless of the efficacy edge.
What is the cash-pay reality if I have diabetes but my insurance denies both?
You are choosing between branded telehealth and compounded options for whichever molecule you and your prescriber decide on, since neither manufacturer offers a self-pay discount on the diabetes brand. Ozempic branded telehealth runs around $399/mo; Mounjaro branded telehealth runs around $499/mo. Compounded versions - where a 503A pharmacy still fills case-by-case post-shortage - run lower (Ozempic-molecule around $199/mo, Mounjaro-molecule around $299/mo) but availability narrowed sharply after the FDA closed the shortage-based compounding pipeline in 2024-2025.
Can I ask my doctor to prescribe Wegovy or Zepbound instead if I have diabetes?
Yes, and it is a completely legitimate conversation to have. Both Wegovy and Zepbound are approved for chronic weight management, and there is no rule against a patient with type 2 diabetes taking a weight-loss-indicated GLP-1 instead of a diabetes-indicated one - the molecules are identical. The tradeoff: insurance coverage logic usually runs the other way (diabetes diagnosis codes trigger coverage for the diabetes brand more reliably than the weight-loss brand), so switching brands for self-pay economics can sometimes cost you insurance coverage you would have had on the diabetes brand. Run both scenarios with your specific plan before deciding.
Does the Ozempic or Mounjaro Savings Card help with any of this?
Only if your insurance already covers the drug for type 2 diabetes. Both savings cards - the Ozempic Savings Card from Novo Nordisk and the Mounjaro Savings Card from Eli Lilly - reduce copay for patients whose commercial insurance already covers the drug; they do not function as a self-pay discount for uninsured or denied patients, and government insurance (Medicare, Medicaid, Tricare, VA) is excluded from both by federal anti-kickback rules. If your insurance denies coverage entirely, the savings card does nothing for you.
Related guides
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.